Emerging evidence has shown that TRIP13 may serve as an oncogene and could be correlated with poor survival in patients with hepatocellular carcinoma,[9] breast cancer,[10] and clear cell renal cell carcinoma (ccRCC).[11] Pan-cancer analysis, which compares differences between various tumors, is crucial for identifying new biomarkers and therapeutic targets for tumors. Here, TRIP13 is linked to nonpapillary renal cell carcinoma.